Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma

[1]  P. Tappenden,et al.  Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals , 2021, PharmacoEconomics.

[2]  G. Leverger,et al.  Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Société Française des Cancers de l’Enfant study , 2015, Haematologica.

[3]  R. Willke,et al.  Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. , 2013, BMJ.

[5]  S. Stock,et al.  Cost Effectiveness of Rituximab for Non-Hodgkin’s Lymphoma , 2012, PharmacoEconomics.

[6]  D. Owens,et al.  State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  R. Marcus,et al.  An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  E. Deconinck,et al.  Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma , 2010, PharmacoEconomics.

[9]  E. Kimby,et al.  Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden , 2008, Acta oncologica.

[10]  J. Hornberger,et al.  Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  J. Hornberger,et al.  Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphoma , 2005, Cancer.

[12]  Andrew R Willan,et al.  Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. , 2005, American heart journal.

[13]  J. Hornberger,et al.  Cost‐effectiveness of rituximab (MabThera®) in diffuse large B‐cell lymphoma in the Netherlands , 2005, European journal of haematology.

[14]  N. Brewer,et al.  Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. , 2004, Health technology assessment.

[15]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[16]  R. Ravasio,et al.  Cost-Effectiveness Analysis of the Addition of Rituximab to CHOP in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma , 2008, Clinical drug investigation.